Dimopoulos, M. Sanz, R.G. Lee, H.-P. Trneny, M. Varettoni, M. Opat, S. D'Sa, S. Owen, R.G. Cull, G. Mulligan, S. Czyz, J. Castillo, J.J. Motta, M. Siddiqi, T. Mesa, M.G. Gorrochategui, M.G. Talaulikar, D. Zinzani, P.L. Askari, E. Grosicki, S. Oriol, A. Rule, S. Kloczko, J. Tedeschi, A. Buske, C. Leblond, V. Trotman, J. Chan, W.Y. Michel, J. Schneider, J. Tan, Z. Cohen, A. Huang, J. Tam, C.S. ASPEN investigators, Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: A substudy of the phase 3 ASPEN trial, Blood advances, (4), 6009-6018, 2020, American Society of Hematology,